Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk

PHASE3CompletedINTERVENTIONAL
Enrollment

327

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

September 26, 2016

Study Completion Date

September 26, 2016

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

gemtuzumab ozogamycin

gemtuzumab ozogamycin = 6mg/m² during the induction course (Day 4) gemtuzumab ozogamycin = 6mg/m² during the first intensive consolidation course (Day 4)

Trial Locations (29)

Unknown

CH Pays d'Aix, Aix

CHU Amiens, Amiens

CHRU Angers, Angers

CH Avignon, Avignon

Centre Hospitalier de la Côte Basque, Bayonne

CHU Hôpital Minjoz, Besançon

CHU Morvan, Brest

CHU Hôtel Dieu, Clermont-Ferrand

CH Louis Pasteur, Colmar

CHU du Bocage, Dijon

CHU Michallon, Grenoble

CHU Dupuytren, Limoges

Institut Paoli Calmette, Marseille

CH Metz Thionvile, Metz

CHU Lapeyronie, Montpellier

CH Muller, Mulhouse

CHU Hôtel Dieu, Nantes

CHU Carémeau, Nîmes

CH La Source, Orléans

Hopital Cochin (AP-HP), Paris

CHU du Haut Lévèque, Pessac

CHU Jean Bernard - La Milétrie, Poitiers

CHU Robert Debré, Reims

CHU Pontchaillou, Rennes

Institut de Cancérologie de la Loire, Saint-Etienne

CHU Hautepierre, Strasbourg

CHU Purpan, Toulouse

CHU Bretonneau, Tours

CHU Brabois, Vandœuvre-lès-Nancy

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Chugai Pharmaceutical

INDUSTRY

collaborator

French Innovative Leukemia Organisation

OTHER

lead

Nantes University Hospital

OTHER